Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of PRDX2 in the HCC cell line HCCLM3 promoted cancer cell proliferation and migration.
|
30747220 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prx2 links ROS homeostasis to stemness of cancer stem cells.
|
30611866 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To further investigate the role of PRP‑1 in chondrosarcoma cells, its effects on cancer stem cell (CSC) populations were determined by analyzing aldehyde dehydrogenase (ALDH) activity, an established marker of CSCs, in association with regulation of the Wnt/β‑catenin signaling.
|
31180539 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Screening of potential biomarkers was performed with 52, and five differentially abundant proteins, peroxiredoxin 2 (PRDX2), thioredoxin (TXN), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), extracellular matrix protein 1 (ECM1), and protein S100 A8 (S100A8), were chosen to undergo validation, for their previously known connection with oxidative stress or cancer.
|
31567534 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, Prx1 and Prx2 are able to bind to a diversity of interaction partners to regulate other various cellular processes in cancer (i.e., regulation of the protein redox status, cell growth, apoptosis, and tumorigenesis).
|
31185618 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monitoring the action of redox-directed cancer therapeutics using a human peroxiredoxin-2-based probe.
|
30087344 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers.
|
30177619 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following initiation of cancer, immunohistochemistry was used to compare the expression of CD44, RKIP and peroxiredoxin 2 at different stages of cancer development.
|
29435053 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Particularly, transforming growth factor-beta-induced protein ig-h3 (Beta ig-h3) and peroxiredoxin-2 (PRDX2) overexpression in the secretome of cancer cell lines was detected and confirmed by Western blot.
|
28261610 |
2017 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer stem cell formation by reducing the levels of peroxiredoxin II and reactive oxygen species in pancreatic cancer cells.
|
29130098 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer.
|
27894099 |
2016 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Treatment with the demethylating agent, 5-aza-dC, but not the histone deacetylase (HDAC) inhibitor, TSA, led to elevated expression in cancer cell lines, indicating that promoter DNA methylation negatively regulates AURKC expression.
|
25990457 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that Prx II has an important role in cancer cell survival via the modulation of signaling molecules involved in apoptosis and the phosphorylation of JNK by the downregulation of ROS levels in A549/GR cells.
|
26021759 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that PrxII is likely to be attributed to a tumor survival factor positively regulating JNK-dependent DNA repair with its inhibition possibly sensitizing cancer cells to chemotherapeutic agents.
|
21148313 |
2011 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our experimental results of PRP-1 action on human chondrosarcoma JJ012 cells demonstrated inactivation, abolishment of Myc oncogene activity usually upregulated in chondrosarcoma cells and other malignancies.
|
18612811 |
2009 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prx II was strongly expressed in mature endothelial cells of benign vascular tumors, whereas it was expressed weakly or not expressed in immature endothelial cells in malignant tumors of Kaposi's sarcoma and angiosarcoma.
|
12963914 |
2003 |